S&P Futures
3,936.25 +38.50 (+0.99%) Dow Futures
31,448.00 +246.00 (+0.79%) Nasdaq Futures
12,051.50 +173.25 (+1.46%) Russell 2000 Futures
1,796.00 +21.10 (+1.19%) Crude Oil
111.65 -0.56 (-0.50%) Gold
1,842.60 +1.40 (+0.08%)
Incannex Healthcare Limited (IXHL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.44 |
| Open | 8.64 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 900 |
| Day's Range | 7.70 - 8.64 |
| 52 Week Range | 5.65 - 96.07 |
| Volume | |
| Avg. Volume | 245,789 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it completed a highly constructive Pre-Investigational New Drug Application ('pre-IND') meeting with the U.S. Food and Drug Administration ('FDA') to discuss the development IHL-42X.
- PR Newswire
Incannex Completes Share Sale and Purchase Agreement to Wholly Acquire APIRx Pharmaceuticals USA, LLC
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, advises that it has entered into a Share Sale and Purchase Agreement to acquire 100% of the issued share capital in APIRx Pharmaceuticals USA, LLC (APIRx) (Acquisition).
- PR Newswire
Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex" or the 'Company'), a clinical stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that IHL-216A was observed to have a strong neuroprotective effect in a widely known model of sports concussion.
